Baricitinib, methotrexate, or baricitinib plus methotrexate in patients with early rheumatoid arthritis who had received limited or no treatment with disease-modifying anti-rheumatic drugs (DMARDs): Results of the Phase 3 RA-BEGIN trial

R. Fleischmann; T. Takeuchi; D. Schlichting; W. Macias; T. Rooney; S. Gurbuz; I. Stoykov; S. Beattie; W. L. Kuo; M. Schiff; M. Dougados

doi:10.1016/S1169-8330(16)30206-X

Baricitinib, methotrexate, or baricitinib plus methotrexate in patients with early rheumatoid arthritis who had received limited or no treatment with disease-modifying anti-rheumatic drugs (DMARDs): Results of the Phase 3 RA-BEGIN trial

R. Fleischmann, T. Takeuchi, D. Schlichting, W. Macias, T. Rooney, S. Gurbuz, I. Stoykov, S. Beattie, W. L. Kuo, M. Schiff, M. Dougados

Vice-President

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	A37
Journal	Revue du Rhumatisme (Edition Francaise)
Volume	83
DOIs	https://doi.org/10.1016/S1169-8330(16)30206-X
Publication status	Published - 2016 Nov 1

ASJC Scopus subject areas

Rheumatology

Access to Document

10.1016/S1169-8330(16)30206-X

Cite this

Fleischmann, R., Takeuchi, T., Schlichting, D., Macias, W., Rooney, T., Gurbuz, S., Stoykov, I., Beattie, S., Kuo, W. L., Schiff, M., & Dougados, M. (2016). Baricitinib, methotrexate, or baricitinib plus methotrexate in patients with early rheumatoid arthritis who had received limited or no treatment with disease-modifying anti-rheumatic drugs (DMARDs): Results of the Phase 3 RA-BEGIN trial. Revue du Rhumatisme (Edition Francaise), 83, A37. https://doi.org/10.1016/S1169-8330(16)30206-X

Baricitinib, methotrexate, or baricitinib plus methotrexate in patients with early rheumatoid arthritis who had received limited or no treatment with disease-modifying anti-rheumatic drugs (DMARDs): Results of the Phase 3 RA-BEGIN trial. / Fleischmann, R.; Takeuchi, T.; Schlichting, D. et al.
In: Revue du Rhumatisme (Edition Francaise), Vol. 83, 01.11.2016, p. A37.

Research output: Contribution to journal › Article › peer-review

Fleischmann, R, Takeuchi, T, Schlichting, D, Macias, W, Rooney, T, Gurbuz, S, Stoykov, I, Beattie, S, Kuo, WL, Schiff, M & Dougados, M 2016, 'Baricitinib, methotrexate, or baricitinib plus methotrexate in patients with early rheumatoid arthritis who had received limited or no treatment with disease-modifying anti-rheumatic drugs (DMARDs): Results of the Phase 3 RA-BEGIN trial', Revue du Rhumatisme (Edition Francaise), vol. 83, pp. A37. https://doi.org/10.1016/S1169-8330(16)30206-X

Fleischmann R, Takeuchi T, Schlichting D, Macias W, Rooney T, Gurbuz S et al. Baricitinib, methotrexate, or baricitinib plus methotrexate in patients with early rheumatoid arthritis who had received limited or no treatment with disease-modifying anti-rheumatic drugs (DMARDs): Results of the Phase 3 RA-BEGIN trial. Revue du Rhumatisme (Edition Francaise). 2016 Nov 1;83:A37. doi: 10.1016/S1169-8330(16)30206-X

@article{122221bbd4ea4d43beb20fb2eb0476b9,

title = "Baricitinib, methotrexate, or baricitinib plus methotrexate in patients with early rheumatoid arthritis who had received limited or no treatment with disease-modifying anti-rheumatic drugs (DMARDs): Results of the Phase 3 RA-BEGIN trial",

author = "R. Fleischmann and T. Takeuchi and D. Schlichting and W. Macias and T. Rooney and S. Gurbuz and I. Stoykov and S. Beattie and Kuo, {W. L.} and M. Schiff and M. Dougados",

year = "2016",

month = nov,

day = "1",

doi = "10.1016/S1169-8330(16)30206-X",

language = "English",

volume = "83",

pages = "A37",

journal = "Revue du Rhumatisme (Edition Francaise)",

issn = "1169-8330",

}

TY - JOUR

T1 - Baricitinib, methotrexate, or baricitinib plus methotrexate in patients with early rheumatoid arthritis who had received limited or no treatment with disease-modifying anti-rheumatic drugs (DMARDs)

T2 - Results of the Phase 3 RA-BEGIN trial

AU - Fleischmann, R.

AU - Takeuchi, T.

AU - Schlichting, D.

AU - Macias, W.

AU - Rooney, T.

AU - Gurbuz, S.

AU - Stoykov, I.

AU - Beattie, S.

AU - Kuo, W. L.

AU - Schiff, M.

AU - Dougados, M.

PY - 2016/11/1

Y1 - 2016/11/1

UR - http://www.scopus.com/inward/record.url?scp=85007614117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007614117&partnerID=8YFLogxK

U2 - 10.1016/S1169-8330(16)30206-X

DO - 10.1016/S1169-8330(16)30206-X

M3 - Article

AN - SCOPUS:85007614117

SN - 1169-8330

VL - 83

SP - A37

JO - Revue du Rhumatisme (Edition Francaise)

JF - Revue du Rhumatisme (Edition Francaise)

ER -

Baricitinib, methotrexate, or baricitinib plus methotrexate in patients with early rheumatoid arthritis who had received limited or no treatment with disease-modifying anti-rheumatic drugs (DMARDs): Results of the Phase 3 RA-BEGIN trial

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this